Clinical Scorecard: Disparities in Secondary Treatment Approaches and Survival Rates for Localized Prostate Cancer Among Racial Groups

At a Glance

Key Highlights

• Black men are 1.6 times more likely to be diagnosed with prostate cancer than White men.
• Under equitable treatment conditions, Black and White patients have similar outcomes.
• Black patients receive fewer definitive treatments and experience delays in treatment.
• Secondary treatment is standard for nearly 20% of patients after primary treatment.
• Less frequent PSA surveillance among Black patients may delay secondary treatment.

Guideline-Based Recommendations

Diagnosis

• Monitor prostate-specific antigen (PSA) levels after primary treatment.

Management

• Implement timely salvage radiation therapy at biochemical recurrence.

Monitoring & Follow-up

• Ensure consistent PSA surveillance to identify recurrent disease.

Risks

• Delays in secondary treatment may contribute to higher mortality rates among Black patients.

Patient & Prescribing Data

Medicare beneficiaries aged 66 years or older diagnosed with localized prostate cancer.

Secondary treatments include radiation therapy, androgen deprivation therapy, and novel systemic therapies.

Clinical Best Practices

• Ensure equitable access to definitive treatments for all racial groups.
• Enhance health literacy and education access to improve treatment outcomes.
• Implement policies to reduce disparities in treatment and surveillance.

Related Resources & Content

• Study on racial disparities in prostate cancer outcomes